A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07465666

Acronym

REAL-HTN

Enrollment

500

Registered

2026-03-12

Start date

2026-09-15

Completion date

2027-08-15

Last updated

2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Angiotensin Receptor-Neprilysin Inhibitor, Sacubitril/valsartan, High blood pressure

Brief summary

The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

1. Adult male or female patients (≥18 years). 2. Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology \[AHA/ACC\] guidelines and/or the 2024 European Society of Cardiology \[ESC\] guidelines). 3. Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi. 4. Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi. Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion. 5. Patients willing to provide written informed consent to participate in the study.

Exclusion criteria

1. Patients with malignant or severe hypertension (systolic blood pressure \[SBP\] ≥180 mmHg, diastolic blood pressure \[DBP\] ≥110 mmHg) at baseline. 2. Patients with secondary causes of hypertension, as determined by the treating physician. 3. Patients with a history of, or at risk of developing, angioedema. 4. Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m\^2). 5. Pregnant or lactating women. 6. Patients with serum potassium level ≥5.5 mmol/L at baseline.

Design outcomes

Primary

Measure	Time frame
Change From Baseline to Week 4 in Mean Sitting SBP	Baseline to Week 4

Secondary

Measure	Time frame	Description
Change From Baseline to Week 4 in Mean Sitting DBP	Baseline to Week 4	—
Change From Baseline to Week 4 in Mean Sitting Pulse Pressure	Baseline to Week 4	—
Proportion of Patients Achieving Target Office Blood Pressure at Weeks 4 and 12	Weeks 4 and 12	Target office blood pressure is defined as SBP \<130 mmHg and DBP \<80 mmHg.

Contacts

CONTACTNovartis Pharmaceuticals

novartis.email@novartis.com+41613241111

STUDY_DIRECTORNovartis Pharmaceuticals

Novartis Pharmaceuticals

Outcome results